We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE icon
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Miscellaneous 1.72%
3 Financials 1.69%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$235M 9.43%
16,459,128
+552,448
+3% +$8.38M
2013 Q2
22 quarters
ATRA icon
2
Atara Biotherapeutics
ATRA
$96M
$153M 6.17%
176,585
+7,836
+5% +$7.28M
2014 Q4
16 quarters
FATE icon
3
Fate Therapeutics
FATE
$232M
$133M 5.35%
10,359,666
– –
2015 Q2
14 quarters
XNCR icon
4
Xencor
XNCR
$1.74B
$112M 4.49%
3,084,703
+54,560
+2% +$2M
2016 Q4
8 quarters
WVE icon
5
Wave Life Sciences
WVE
$609M
$94.1M 3.78%
2,237,607
-35,700
-2% -$1.59M
2015 Q4
12 quarters
ARGX icon
6
argenx
ARGX
$51.5B
$92.3M 3.71%
960,961
-13,545
-1% -$1.2M
2017 Q4
4 quarters
ALLK icon
7
DELISTED
Allakos
ALLK
$88.8M 3.57%
1,698,648
+238,756
+16% +$12M
2018 Q3
1 quarter
FOLD icon
8
DELISTED
Amicus Therapeutics
FOLD
$79.7M 3.21%
8,323,217
-79,400
-0.9% -$873K
2013 Q2
22 quarters
IFRX icon
9
InflaRx
IFRX
$218M
$74M 2.98%
2,035,400
+10,500
+0.5% +$323K
2017 Q4
4 quarters
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$72.9M 2.93%
4,060,529
+2,282,229
+128% +$46.6M
2018 Q2
2 quarters
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$69.1M 2.78%
2,537,300
+363,600
+17% +$10M
2018 Q3
1 quarter
ALDR
12
DELISTED
Alder Biopharmaceuticals
ALDR
$66.7M 2.68%
6,505,766
– –
2016 Q3
9 quarters
RGNX icon
13
Regenxbio
RGNX
$454M
$56.8M 2.29%
1,354,742
-301,323
-18% -$17.7M
2017 Q1
7 quarters
CI icon
14
Cigna
CI
$76.5B
$52.3M 2.11%
275,610
-94,590
-26% -$19.7M
2018 Q3
1 quarter
IMGN icon
15
DELISTED
Immunogen Inc
IMGN
$52.2M 2.1%
10,884,607
-1,424,428
-12% -$8.64M
2017 Q1
7 quarters
BOLD icon
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$49.1M 1.97%
2,301,667
+58,311
+3% +$1.5M
2016 Q3
9 quarters
LIVN icon
17
LivaNova
LIVN
$4.19B
$47.1M 1.89%
514,987
-84,301
-14% -$9.05M
2017 Q2
6 quarters
BMY icon
18
Bristol-Myers Squibb
BMY
$121B
$44.4M 1.79%
+854,700
New +$45.9M
2018 Q4
0 quarters
EHTH icon
19
eHealth
EHTH
$19.5M
$41.9M 1.69%
1,091,395
-381,200
-26% -$12.8M
2016 Q4
8 quarters
XERS icon
20
Xeris Biopharma Holdings
XERS
$1.78B
$41M 1.65%
2,412,641
+1
+0% +$20
2018 Q2
2 quarters
EPZM
21
DELISTED
Epizyme, Inc
EPZM
$40.9M 1.64%
6,637,278
+4,389,089
+195% +$33.5M
2017 Q3
5 quarters
SRRK icon
22
Scholar Rock
SRRK
$4.82B
$40.5M 1.63%
1,761,407
-11,700
-0.7% -$265K
2018 Q2
2 quarters
TNDM icon
23
Tandem Diabetes Care
TNDM
$1.11B
$39.5M 1.59%
1,039,750
-29,920
-3% -$1.06M
2018 Q3
1 quarter
MDT icon
24
Medtronic
MDT
$121B
$38.2M 1.54%
+419,900
New +$39.2M
2018 Q4
0 quarters
QURE icon
25
uniQure
QURE
$1.45B
$37.6M 1.51%
1,303,422
-336,478
-21% -$9.36M
2018 Q2
2 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.